A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1181-1187

  Chakravarty, G ^a   Redkar, A ^a   Mittra, I ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Bow cytometry; Breast cancer; Genomic sequencing; Immunohistochemistry; p53 mutation; Polymerase chain reaction single strand conformation polymorphism

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0029827384     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.514     Document Type: Article

References (31)

1. ALLRED DC, CLARK GM, ELLEDGE R, FUQUA SA, BROWN RW, CHAMNESS GC, OSBORNE CK AND MCGIRE WL. (1993). Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node negative breast cancer. J. Natl Cancer Inst., 85, 200-206.
2. BANKS L, MATLASHEWSKI G AND CRAWFORD L. (1986). Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem., 159, 529-534.
3. BARTEK J, BARTKOVA J, VOJTSEK B, STASKOVA Z, REJTHAR A, KOVARIK J AND LANE DP. (1990b). Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int. J. Cancer, 46, 839-844.
4. BARTEK J, IGGO R, GANNON J AND LANE DP. (1990a). Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5, 893-899.
5. CATTORETTI G, RILKE F, ANDREOLAR S, D'AMATO L AND DELIA D. (1988). p53 expression in breast cancer. Int. J. Cancer, 41, 178-183,
6. CHO Y, GORIA S, JEFFREY PD AND PAVLETICH NP. (1994). Crystal structure of a p53 tumour suppressor - DNA complex: understanding tumorigenic mutations. Science, 265, 346-355.
7. DAVIDOFF AM, HUMPHREY PA, IGLEHART JD AND MARKS JR. (1991). Genetic basis for p53 overexpression in human breast cancer. Proc. Natl Acad. Sci. USA, 88, 5006-5010.
8. DENG G, CHEN LC, SCHOTT DR, THOR A, BHARGAVA V, LJUNG BM, CHEW K AND SMITH HS. (1994). Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res., 54, 499-505.
9. GANNON JV, GREAVES R, IGGO R AND LANE DP. (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J., 9, 1595-1602.
10. HALL PA AND LANE DP. (1994). p53 in tumour pathology: Can we trust immunohistochemistry? - Revisited! J. Pathol., 172, 1-4.
11. HALL PA, MCKEE PH, MENAGE HD, DOVER R AND LANE DP. (1993). High levels of p53 protein in UV irradiated human skin. Oncogene, 8, 203-207.
12. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B AND HARRIS CC. (1991). p53 mutations in human cancers. Science, 253, 49-53.
13. IGGO R, GATTER K, BARTEK J, LANE D AND HARRIS AL. (1990). Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 335, 675-679.
14. ISOLA J, VISAKORPI T, HOLLI K AND KALLIONIEMI OP. (1992). Association of overexpression of tumour suppressor protein p53 with rapid cell proliferation and poor prognosis in node negative breast cancer patients. J. Natl Cancer Inst., 84, 1109-1114.
15. KOHLER MF, NISHI H, HUMPHREY PA, SARKI H, MARKS J, BAST RC, CLARKE PEARSON DL, BOYD J AND BERCHUCK A. (1993). Mutation of the p53 tumour suppressor gene is not a feature of endometrial hyperplasia. Am. J. Obstet. Gynecol., 169, 690-694.
16. LANE DP. (1994). The regulation of p53 function: Steiner award lecture. Int. J. Cancer, 57, 623-627.
17. LEVINE AJ, PERRY ME, CHANG A, SILVER A, DITTMER D, WU M AND WELSH D. (1994). The 1993 Walter Hubert Lecture: the role of the p53 tumour suppressor gene in tumorigenesis. Br. J. Cancer, 69, 409-416.
18. MANIATIS T, FRITSCH J AND SAMBROOK J. (eds). (1982). Molecular Cloning: a Laboratory Manual. Cold Spring Harbour Laboratory Press: Cold Spring Harbour, NY.
19. MATELASHEWSKI G, BANKS L, PIM D AND CRAWFORD L. (1986). Analysis of human p53 protein and mRNA levels in normal and transformed cells. Eur. J. Biochem., 154, 665-672.
20. MILNER J AND MEDCALF EA. (1991). Cotranslation of activated mutant p53 with wild type drives the wild type p53 into the mutant conformation. Cell, 65, 765-774.
21. MOLL UM, LAQUAGLIA M, BENARD J AND RIOU G (1995). Wild type p53 protein undergoes cytoplasmic sequesteration in undifferentiated neuroblastomas but not in differentiated tumours. Proc. Natl Acad. Sci. USA, 92, 4407-4411.
22. NAVONE NM, TRONCOSO P, PISTERS LL, GOODROW TL, PALMER JL, NICHOLS WW, ESCHENBACH ACV AND CONTI CJ. (1993). p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Nutl Cancer Inst., 85, 1657-1669.
23. NIGRO JM, BAKER SJ, PREISINGER AC, JESSUP JM, HOSTETTER R, CLEARY K, BIGNER SH, DAVIDSON N, BAYLIN S, DEVILEE P, GLOVER T, COLLINS FS, WESTON A, MODALI R, HARRIS CC AND VOGELSTEIN B. (1989). Mutations in p53 gene occur in diverse human tumour types. Nature, 342, 705-708.
24. ORITA S, SUZUKI Y, SEKIYA T AND HAYASHI K, (1989). Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 5, 874-879.
25. OSBORNE RJ, MERLO GR, VENESIO MT, LISCIA VDS, CAPPA APM, TAKAHASHI CT, NAU MM, CALLAHAN R AND MINNA JD. (1991). Mutations in the p53 gene in primary human breast cancers. Cancer Res., 51, 6194-6198.
26. RASBRIDGE SA, GILLET CE, SEYMOUR AM AND MILLIS RR (1993). The effect of chemotherapy on histological and biological features of breast carcinoma. J. Pathol., 169 (suppl.), 191.
27. RODRIGUES NR, ROWAN A, SMITH ME, KERR IB, BODOMER WF, GANNON J AND LANE DP. (1990). p53 mutations in colorectal cancer. Proc. Natl Acad. Sci. USA, 87, 7555-7559.
28. SOTO D AND SUKUMAR S. (1992). Improved detection of mutations in the p53 gene in human tumours as single stranded conformation polymorphs and double stranded heteroduplex DNA. PCR Methods Applications, 2, 96-98.
29. THOR AD, MOORE DH, EDGERTON SM, KAWASAKI ES, REIHSOUS E, LYNCH HT, MAARCUS JN, SCHWARTZ L, CHEN LC, MAYALL BH AND SMITH HS. (1992). Accumulation of p53 tumour suppressor gene protein: an independnet marker of prognosis in breast cancer. J. Natl Cancer Inst., 84, 845-855.
30. TOGUCHIDA J, YAMAGUCHI T, DAYTON SH, BEAUCHAMP RL, HERRERA GE ISHIZAKI K, YAMAMURO T, MEYERS PA, LITTLE JB, SASAKI MS, WEICHSEL BAUM RR AND YANDELL DW, (1992). Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N. Engl. J. Med., 326, 1301-1308.
31. WYNFORD-THOMAS D. (1992). p53 in tumour patholoogy: can we trust immunocytochemistry? J. Pathol, 166, 329-330.